Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Affinity and Avidity01:41

Affinity and Avidity

36.8K
Overview
36.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

N, S Co-Doped Carbon Derived From Lignosulfonate Sodium Synergized With Bismuth for Enhanced Sodium-Ion Storage.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Efficacy and safety of inhaled ambroxol hydrochloride solution in Chinese pediatric patients with acute lower respiratory tract infections: a real-world, multicenter, open-label, single-arm study.

Translational pediatrics·2026
Same author

De novo variants in NPTN cause a neurodevelopmental disorder with autism and neuroplastin-PMCA hypofunction.

Genome medicine·2026
Same author

Recombinant human IGF-1 alleviates dyslipidemia induced by lactational maternal dietary restriction.

Frontiers in pediatrics·2026
Same author

Engineering Fc heterodimerization via asymmetric β-strand reconfiguration for bispecific antibody assembly.

Journal of biological engineering·2026
Same author

Subplate neurons: potential targets for dysfunction after hypoxic-ischemic brain injury.

Experimental neurology·2026

Related Experiment Video

Updated: Oct 5, 2025

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.5K

Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity.

Edurne Rujas1,2,3,4, Hong Cui1, Jonathan Burnie5,6

  • 1Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada.

Proceedings of the National Academy of Sciences of the United States of America
|January 22, 2022
PubMed
Summary
This summary is machine-generated.

Researchers engineered a novel molecule combining multiple HIV-1 broadly neutralizing antibodies (bNAbs) for enhanced potency and broad coverage against HIV-1. This innovative design shows promise for therapeutic applications.

Keywords:
HIV-1antibodyneutralizationprotein engineering

More Related Videos

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.8K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.7K

Related Experiment Videos

Last Updated: Oct 5, 2025

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.5K
Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay
05:15

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle VLP-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

3.8K
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

19.7K

Area of Science:

  • Immunology
  • Virology
  • Biotechnology

Background:

  • HIV-1 broadly neutralizing antibodies (bNAbs) are crucial for therapeutic strategies.
  • Existing bNAbs may lack sufficient breadth or potency for monotherapy.
  • Engineering multispecific antibodies can enhance neutralization efficacy.

Purpose of the Study:

  • To engineer a single molecule combining multiple HIV-1 bNAbs.
  • To enhance the potency and breadth of HIV-1 neutralization.
  • To achieve therapeutic-level efficacy using a novel antibody design.

Main Methods:

  • Genetic fusion of antibody Fab fragments to human apoferritin light chain.
  • Creation of a multispecific and avid antibody molecule.
  • Incorporation of Fc regions and modulation of Fc receptor binding for in vivo bioavailability.

Main Results:

  • The engineered molecule achieved a median IC50 of 0.0009 µg/mL.
  • Demonstrated 100% neutralization coverage of 118 HIV-1 pseudovirus isolates.
  • Showed a 32-fold enhancement in neutralization potency compared to antibody mixtures.
  • Achieved IgG-like bioavailability in vivo.

Conclusions:

  • The engineered multispecific antibody molecule exhibits superior potency and breadth against HIV-1.
  • This plug-and-play antibody design offers a robust platform for therapeutic development.
  • The approach is relevant for indications requiring simultaneous multispecificity and avidity.